利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

421 条记录 (耗时 0.04 秒)

    T CELL RECEPTOR WITH SPECIFICITY FOR MYELOPEROXIDASE PEPTIDE AND USES THEREOF
    3.
    发明申请
    T CELL RECEPTOR WITH SPECIFICITY FOR MYELOPEROXIDASE PEPTIDE AND USES THEREOF 审中-公开
    具有特异性的三环氧化酶肽的细胞受体及其用途

    公开(公告)号：WO2016184592A1

    公开(公告)日：2016-11-24

    申请号：PCT/EP2016/056802

    申请日：2016-03-29

    申请人： KLINIKUM RECHTS DER ISAR DER TU MÜNCHEN

    发明人： KRACKHARDT, Angela ,  KLAR, Richard

    IPC分类号： C07K14/725

    CPC分类号： C07K14/7051 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/70535 ,  C07K2319/30 ,  C07K2319/55

    摘要： The present invention relates to T cell receptors (TCRs) with specificity for a myeloperoxidase peptide. The present invention further relates to soluble TCR constructs, chimeric TCRs, bi-specific antibodies, nucleic acids, expression constructs and cells comprising said TCRs or TCR constructs. Moreover, the present invention relates to pharmaceutical compositions comprising such TCRs, soluble TCR constructs, chimeric TCRs, bi-specific antibodies, nucleic acids, expression constructs and/or cells. The present invention further relates to the use of such TCRs, soluble TCR constructs, chimeric TCRs, bi-specific antibodies, nucleic acids or expression constructs for generating genetically modified lymphocytes and to their use as medicaments, preferably in the detection, diagnosis, prognosis, prevention and/or treatment of a hematological neoplasia involving the expression of myeloperoxidase, preferably a leukemia involving the expression of myeloperoxidase. The present invention further relates to methods of detecting, diagnosing, prognosing, preventing and/or treating a hematological neoplasia involving the expression of myeloperoxidase, preferably a leukemia involving the expression of myeloperoxidase.

    摘要翻译： 本发明涉及对髓过氧化物酶肽具有特异性的T细胞受体（TCR）。 本发明还涉及可溶性TCR构建体，嵌合TCR，双特异性抗体，核酸，表达构建体和包含所述TCR或TCR构建体的细胞。 此外，本发明涉及包含这种TCR，可溶性TCR构建体，嵌合TCR，双特异性抗体，核酸，表达构建体和/或细胞的药物组合物。 本发明还涉及这样的TCRs，可溶性TCR构建体，嵌合TCR，双特异性抗体，用于产生遗传修饰的淋巴细胞的核酸或表达构建体及其作为药物的用途的用途，优选在检测，诊断，预后， 预防和/或治疗涉及髓过氧化物酶表达的血液肿瘤，优选涉及髓过氧化物酶表达的白血病。 本发明还涉及检测，诊断，预后，预防和/或治疗涉及骨髓过氧化物酶表达的血液肿瘤的方法，优选涉及髓过氧化物酶表达的白血病。

    MODIFIED IL-2 VARIANTS THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    6.
    发明申请
    MODIFIED IL-2 VARIANTS THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES 审中-公开
    修饰的IL-2变体，其选择性地激活用于治疗自身免疫性疾病的调节性T细胞

    公开(公告)号：WO2016025385A1

    公开(公告)日：2016-02-18

    申请号：PCT/US2015/044462

    申请日：2015-08-10

    申请人： DELINIA, INC.

    发明人： GREVE, Jeffrey

    IPC分类号： A61K38/20 ,  C07K14/55 ,  C07K17/08

    CPC分类号： C07K14/55 ,  A61K38/00

    摘要： The invention described herein is a novel IL-2 protein with selective agonist activity for Regulatory T cells and with an additional amino acid substitution that enable chemical conjugation with Polyethyene Glycol (PEG) that increase circulating half-life compared to the IL-2 selective agonist alone. A preferred IL-2 selective agonist variant is IL2/N88R/C125S/D109C.

    摘要翻译： 本文描述的本发明是具有针对调节性T细胞的选择性激动剂活性的新型IL-2蛋白，并且具有与IL-2选择性激动剂相比增加循环半衰期的与聚乙二醇（PEG）进行化学偶联的另外的氨基酸取代 单独。 优选的IL-2选择性激动剂变体是IL2 / N88R / C125S / D109C。

    IL4 CONJUGATED TO ANTIBODIES AGAINST EXTRACELLULAR MATRIX COMPONENTS
    10.
    发明申请
    IL4 CONJUGATED TO ANTIBODIES AGAINST EXTRACELLULAR MATRIX COMPONENTS 审中-公开
    IL4与抗细胞基质组分的抗体结合

    公开(公告)号：WO2014173570A1

    公开(公告)日：2014-10-30

    申请号：PCT/EP2014/053998

    申请日：2014-02-28

    申请人： PHILOGEN S.P.A.

    发明人： HEMMERLE, Teresa ,  NERI, Dario

    IPC分类号： A61P37/00 ,  A61P19/02 ,  A61P17/06 ,  A61P3/10 ,  A61K47/48

    CPC分类号： C07K14/5406 ,  A61K31/573 ,  A61K38/00 ,  A61K38/2026 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/6813 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/545 ,  A61P15/00 ,  A61P17/06 ,  A61P19/02 ,  A61P35/00 ,  C07K14/5428 ,  C07K14/5434 ,  C07K14/55 ,  C07K14/70578 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/626 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/035 ,  C07K2319/30 ,  A61K2300/00

    摘要： A conjugate comprising interleukin-4 (IL4) and a specific binding member is disclosed. The specific binding member preferably binds an extra-cellular matrix component associated with neoplastic growth and/or angiogenesis, and the conjugate may be used for targeting IL4 to tissues in vivo. In particular, the therapeutic use of such conjugates in the treatment of a disease/disorder, such as cancer and/or autoimmune diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS), endometriosis, inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, and periodontitis is envisaged. Other diseases which may be treated or prevented using the conjugates include autoimmune insulitis and diabetes, in particular autoimmune diabetes. In the treatment of cancer, the conjugate may be administered in combination with a conjugate comprising either interleukin-12 (IL12) or interleukin-2 (IL2) and a specific binding member. In the treatment of autoimmune diseases, the conjugate may be administered in combination with a glucocorticoid, such as dexamethasone.

    摘要翻译： 公开了包含白细胞介素-4（IL4）和特异性结合成员的缀合物。 特异性结合成员优选结合与肿瘤生长和/或血管生成相关的细胞外基质组分，并且缀合物可用于体内靶向IL4至组织。 特别地，这种缀合物在治疗疾病/病症例如癌症和/或自身免疫疾病（包括类风湿性关节炎（RA）），多发性硬化症（MS），子宫内膜异位症，炎性肠病（IBD），牛皮癣中的治疗用途 ，牛皮癣关节炎和牙周炎。 可以使用缀合物治疗或预防的其它疾病包括自身免疫性胰岛炎和糖尿病，特别是自身免疫性糖尿病。 在癌症的治疗中，缀合物可以与包含白细胞介素-12（IL12）或白细胞介素-2（IL2））和特异性结合成员的缀合物组合施用。 在自身免疫疾病的治疗中，缀合物可以与糖皮质激素如地塞米松组合施用。